The ACR and the ARHP have a long, rich history of collaboration, spanning close to 25 years together. Our predecessors saw the value of an interprofessional team and having an organization that brings together a vast number of constituencies. The result was these two organizations coming together in 1994 when the ARHP became a division…
Picture this: It’s 3 o’clock in the morning. You can’t sleep. You settle in front of the television to watch a rerun of Dirty Dancing. And then it hits you: Ask your doctor. Even as your eyelids sag, some part of your primitive forebrain snaps to attention. Medical training has turned us all into multitaskers,…
NEW YORK (Reuters Health)—Solid evidence suggests that anticonvulsants provide no benefit for low back or lumbar radicular pain and a high risk of harm, researchers say. “We started the study because these drugs were increasingly being used for low back pain and radiating leg pain, without the support of strong evidence of effectiveness,” principal investigator…
Two years ago, veteran leaders of the Pennsylvania Rheumatology Society (PRS)—established 20 years prior—made an important decision to get early career rheumatologists more involved. “We thought younger rheumatologists were under-represented, and we wanted to give them a voice [so they would] better understand a wider range of practice issues our society could address,” explains Alfred…
New research suggests circulating hsa-miR-122-5p and hsa-miR-4516 may become diagnostic biomarkers for osteoporosis. The study found the presence of these microRNAs were associated with osteoporotic fragility fractures and reduced bone mineral density…
Within 10 years of diagnosis, 23–45% of patients with rheumatic and musculoskeletal disease may become unemployed due to disease-related disability. Intervention programs may be necessary to prevent this work loss. New research examined if a vocational rehabilitation program delivered by occupational and physical therapists can benefit this patient population…
The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…
Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has…
Attended by over 15,000 rheumatology professionals from over 100 countries, the ACR/ARHP Annual Meeting is the largest rheumatology meeting in the world and the premier educational event for physicians, health professionals and scientists who treat or research rheumatic and musculoskeletal diseases. The 2018 Annual Meeting will be held Oct. 19–24 in Chicago. Attendees will be…
CHICAGO—As good an option as hydroxychloroquine (HCQ) is for many patients with rheumatic diseases, such as rheumatoid arthritis and especially lupus, safety must be an important consideration, an expert said at this April’s ACR State-of-the-Art Clinical Symposium. The use of the antimalarial has become a controversial subject, with clinicians trying to balance the drug’s disease-modifying…